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have an even higher risk of developing TB and trans-
mitting nosocomial infection.3,6 
The Academic Unit for Infection Prevention and 
Control (UIPC), based in the University of Stellenbosch, 
Western Cape, South Africa, has set up an IPC pro-
gramme with speciﬁ c policies and in-service training to 
reduce TB transmission among patients, visitors and 
health care workers in a central academic hospital 
(CAH) in Cape Town. IPC at the CAH includes context-
speciﬁ c administrative processes (protocols, segrega-
tion and isolation of infectious patients), ventilation 
(natural and mechanical) and the use of personal pro-
tective equipment (PPE), such as masks, respirators 
and gloves.3 It has been shown that the implementa-
tion of administrative controls, environmental con-
trols and PPE effectively reduces transmission of TB in 
health care facilities.6 
Although TB care in South Africa is mainly com-
munity-based, prevalence surveys and ﬁ eld observa-
tions show that a signiﬁ cant number of patients con-
tinue to present to hospitals.7 At the CAH, TB patients 
are often admitted due to comorbidities, such as HIV/
AIDS and treatment for drug-resistant TB. 
The emergence of multidrug-resistant (MDR-) and 
extensively drug-resistant TB (XDR-TB) are of partic-
ular concern to IPC and health care cost manage-
ment. These TB strains are resistant to the main anti-
tuberculosis drugs, and require a longer treatment 
regimen of 20 months or more, resulting in higher 
treatment costs.8 Reduction in TB, including MDR- and 
XDR-TB, is dependent on effective diagnosis, treatment 
and improved communications between the hospital, 
the laboratory and its down-referral clinics.9 
In South Africa, no studies assessing the costs of 
in-patient-based TB care, including diagnosis, manage-
ment and IPC, have been published. In a resource-
limited environment, an adequate costing study is 
necessary for data on the cost implications of IPC per 
patient diagnosed and treated.10 It was therefore im-
portant for the UIPC to investigate the cost of in-
p atient TB management, including the use of TB-IPC, 
in the CAH. This study will ﬁ ll an important gap in 
the literature by providing cost estimates of in-patient-
based TB care and by identifying areas of weakness in 
IPC measures. Furthermore, cost reduction per TB case 
prevented can be determined. 
The objectives of the study were to estimate the 
costs associated with the management (diagnosis, 
treatment, IPC) of pulmonary TB in-patients at a CAH, 
and to evaluate adherence to TB-IPC protocol recom-
mendations, such as PPE use, during pulmonary TB 
in-patient care at a CAH.
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Setting: South Africa reports more cases of tuberculosis 
(TB) than any other country, but an up-to-date, precise 
estimate of the costs associated with diagnosing, treating 
and preventing TB at the in-patient level is not available. 
Objective: To determine the costs associated with TB 
management among in-patients and to study the use of 
personal protective equipment (PPE) at a central academic 
hospital in Cape Town. 
Design: Retrospective and partly prospective cost analysis 
of TB cases diagnosed between May 2008 and October 
2009.
Results: The average daily in-patient costs were US$238; 
the average length of stay was 9.7 days. Mean laboratory 
and medication costs per stay were respectively US$26.82 
and US$8.68. PPE use per day cost US$0.99. The average 
total TB management costs were US$2373 per patient. 
PPE was not always properly used.
Discussion: The costs of in-patient TB management are 
high compared to community-based treatment; the main 
reason for the high costs is the high number of in-patient 
days. An efficiency assessment is needed to reduce costs. 
Cost reduction per TB case prevented was approximately 
US$2373 per case. PPE use accounted for the lowest 
costs. Training is needed to improve PPE use. 
South Africa ranks ﬁ fth among the 22 high tuber-culosis (TB) burden countries in terms of inci-
dence, and seventh in terms of overall TB burden. The 
2011 World Health Organization report on TB indi-
cates a prevalence of 795 per 100 000 population and 
an incidence of 981/100 000 in South Africa.1 At 1000/ 
100 000 population, the Western Cape Province has 
the highest recorded TB incidence in South Africa.2 
TB is the most common opportunistic infection and 
the leading cause of death in persons with HIV/AIDS 
(human immunodeﬁ ciency virus/acquired immune-
deﬁ ciency syndrome).3–5 
TB infection prevention and control (IPC) is a com-
bination of processes and measures aimed at mini-
mising the risk of TB transmission, both in health care 
facilities and at the community level. Effective man-
agement of TB in hospitals is essential to prevent 
transmission among patients, health care workers and 
visitors.5 Health care workers are at higher risk due to 
frequent exposure to patients with TB. The number of 
persons with HIV/AIDS attending health care facilities 
has increased in South Africa; such persons are at an 
increased risk of developing TB. Moreover, if health 
care workers themselves are immune-suppressed they 
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METHODOLOGY 
Design
A retrospective and partly prospective cost analysis was per-
formed. The analysis was conducted from a provider’s perspective, 
as we examined the costs to the health service, including in-
p atient processes and hospital care. This means that all direct and 
non-direct health care costs were included; however, direct non-
health care costs, such as patient travel and time costs, were ex-
cluded.11–13 The unit cost of health services was deﬁ ned as the full 
economic costs per patient treated.11,12 To be able to determine 
the costs in as detailed a manner as possible, the ingredient-based 
costing method was used, i.e., each component of TB manage-
ment was calculated and a unit cost was derived for each.10 For 
this, cost-analysis market prices were used, as they represented 
the most precise estimation of the costs in daily practice.11 Costs 
were expressed in terms of monetary value (2009 US$). 
Data collection
TB management costs at the CAH consisted of in-patient days, 
laboratory tests, medications and PPE, including masks, respira-
tors, gloves, aprons and disinfectant. To calculate the costs of an 
in-patient day, we used the basic accounting system at the hospi-
tal, including all patients admitted and treated for pulmonary TB 
during the period from May 2008 to October 2009. Accounting 
heads were used to determine in-patient day costs; the costs were 
then added up and divided by the patient-day equivalent (PDE). 
PDE was calculated by adding the number of in-p atients plus one 
third of out-patient visits. This ratio is based on primary data col-
lected from Western Cape hospitals, which assumes that an in-
p atient day requires three times more overhead resources than an 
out-patient day.14 In other words, this ratio provides information 
on the costs of one day of hospital admission or three out-patient 
visits. The components of the costs of an in-p atient stay are listed 
in Table 1. Costs for laboratory tests and medications were not 
i ncluded in calculating the cost of an in-p atient day, as we chose 
to calculate these costs speciﬁ cally for TB. 
Other costs included diagnostic laboratory tests and drug pre-
scriptions. Clinicom, an electronic patient database, was accessed 
to identify patients diagnosed and admitted to the hospital with 
pulmonary TB between May 2008 and October 2009. A total of 
200 patients were included in the study. 
To determine laboratory costs, we used the National Health 
Laboratory Service (NHLS) database. This is updated daily, captur-
ing laboratory test requests for each patient. For patients found in 
the Clinicom database, we selected only TB-speciﬁ c laboratory 
tests, as shown in Table 2. TB-speciﬁ c medication data were ex-
tracted from the electronic database of the hospital pharmacy (Ta-
ble 3). The laboratory test prices from the NHLS and medication 
prices from the pharmacy were used to determine the prices of 
the items identiﬁ ed and measured.
Use of personal protective equipment
In line with the TB-IPC protocol of the hospital, all in-patients 
with pulmonary TB were reported to the IPC nursing team. PPE 
use per day was measured using several randomly selected obser-
vations on the wards by the principal investigator. The type and 
quantity of PPE used by personnel and visitors when in contact 
with TB patients were documented. These observations were used 
to investigate the volume of PPE for the costing analysis and to 
evaluate the TB-IPC protocol. Nine patients were observed for 24 h 
each, spread over a time period of 4 weeks.
TABLE 1 Types of expenditure and categories of costs 
of in-patient day*
Category Expenditure type
Personnel Personnel: salaries, pension, medical aid allowance, bonus, 
scarce skills, housing allowance, commuting, normal 
overtime, incentives, sessional, periodical, discretionary 
leave, shift allowance, other remuneration, uniform 
allowances
Agency staff: administration, medical, nursing, pharmacy 
Joint staff: Cape Peninsula University, University of 
Stellenbosch, basic accounting system journals
Goods and 
services
Surgical supplies, blood, X-ray consumables, private 
medical services (magnetic resonance imaging, positron 
emission tomography/computed tomography), assistive 
devices, clinical engineering, hospital engineering, 
cleaning services, security services, linen/laundry 
management, waste removal, photo stats (photocopier 
rental, copies), burial services 
Overheads Overhead: catering, communication, stationery, training, 
computer services and systems, courier and postal, 
power, water, uniforms purchased, pest control, 
consultants and contractors, grounds and gardens, 
steam, municipal services, gases and rentals, fuel oil and 
lubricants
Capital 
equipment
Capital equipment, current equipment
* Although not a monthly cost, the added cost of financial assets, software and in-
tangible assets were included in the study analysis.
TABLE 2 TB laboratory tests performed at the NHLS
Fluid preparation for TB microscopy
PCR tuberculosis
Mycobacterium tuberculosis complex
Identification of mycobacteria
Special TB culture materials
TB fluorescence microscopy 
Standard TB microscopy
DST against PZA
TB differentiation
DST per drug
Culture TB
No growth on culture 
Radiometric mycobacterium antibiotic sensitivity
Identification of M. tuberculosis 
TB = tuberculosis; NHLS = National Health Laboratory Service; PCR = polymerase 
chain reaction; DST = drug susceptibility testing; PZA = pyrazinamide.
TABLE 3 Anti-tuberculosis drugs from pharmacy
EMB HCl
Ethionamide
INH
Kanamycin sulphate
Moxifloxacin
Ofloxacin
PZA
RMP+EMB+INH+PZA combination
RMP
RMP+INH combination
RMP+INH+PZA combination tablet
Streptomycin 
Terizidone 
EMB = ethambutol; HCl = hydrogen chloride; INH = isoniazid; PZA = pyrazin-
amide; RMP = rifampicin.
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Data analysis 
The cost of an in-patient day and that of a day of PPE use were 
multiplied by the average length of stay of a TB patient at the 
hospital; this was then added to laboratory and medication costs. 
We used a ZAR-USD exchange rate of 1 ZAR = USD 0.10729, as at 
the beginning of 2009. Excel (Microsoft, Redwoods, WA, USA) 
and SPSS (Statistical Package for the Social Sciences Inc, Chicago, 
IL, USA) were used to process data. 
Ethical approval
Ethical approval was granted by the Health Research Ethics Com-
mittee at the Faculty of Health Sciences, University of Stellen-
bosch, Cape Town, and operational approval by the Department 
of Health, Western Cape Province. Participant information and 
informed consent was provided. Patients were informed that the 
results of the study would be made public and published. 
RESULTS
In-patient day costs were calculated using all patients with pul-
monary TB at the hospital. The average cost of an in-patient day 
was US$238 (95% conﬁ dence interval [CI] 193–238; range 205–
299; Table 4). 
Laboratory and medication costs
Of the 200 TB patients included in the analysis, 24.5% (n = 49) 
had no records in either the NHLS or the pharmacy database, and 
a value of zero was therefore used for their laboratory and medi-
cation costs. These patients were included in the differential 
analysis as they received treatment and were perceived to rep-
resent in-patient costs for pulmonary TB at the hospital most 
accurately. 
Mean laboratory costs were US$26.82 (95%CI 36.59–90.22, 
range 0.00–174.88). Patients with high costs underwent several 
costly laboratory tests, possibly when MDR-TB was suspected. No 
data on the deﬁ nitive diagnosis (i.e., susceptible or resistant) of 
these patients were available. Mean medication costs were US$8.68 
(95%CI 34.88–52.23, range 0.00–133.36). Patients with high labo-
ratory costs often also had higher medication costs. 
Costs of personal protective equipment
The average cost of a day of PPE use was US$0.99 (95%CI 0.26–
1.72, range 0.42–1.40). PPE costs for suspected MDR-TB cases were 
slightly higher than for drug-susceptible TB, as more masks were 
used. PPE included surgical masks, gloves, aprons and hand dis-
infectant. N95 respirators were not used, although these were rec-
ommended for MDR-TB cases (Table 5). 
Total tuberculosis management costs
Using a random sample of 70 TB patients from our population, 
we calculated the average length of stay to be 9.7 days (range 0–
47). The length of the study lent itself to a point prevalence anal-
ysis, which gave an idea of the average length of stay during the 
time period. The in-patient day costs and cost of one day of PPE 
use were multiplied by the average length of stay and added to 
laboratory and medication costs. The total TB management costs 
for an in-patient with TB, using a length of stay of 0 days and one 
of 47 days, were respectively US$36 and US$11 246. The average 
cost of an in-patient TB stay at the hospital was US$2373 (Figure).
Use of personal protective equipment
The use of surgical masks can serve as an indicator of adherence 
to TB-IPC protocol, as they have to be worn when entering the 
patient’s room. The use of other types of PPE, such as gloves and 
aprons, is compulsory during clinical procedures and does not in-
dicate adherence to the TB-IPC protocol. Staff wore a mask during 
26.3% of the room entries, compared to only 15.8% for visitors 
(Table 5). It was observed during data collection that a patient 
with suspected MDR-TB left the isolation room without permis-
sion. On another occasion, another MDR-TB suspect was not ad-
mitted to an isolation room. These observations suggest that IPC 
measures and PPE use were not always applied in clinical practice 
despite TB-IPC protocol recommendations. 
TABLE 4 Cost of an in-patient TB day
Month
Cost category, US$
PDE
Costs of 
in-patient dayPersonnel
Goods and 
services Overheads
Capital 
equipment
Other 
costs*
2008
 May 6 490 749 2 316 798 23 589  40 758      0 43 180 205
 June 7 323 770 3 065 345 11 146  13 913      0 42 586 245
 July 6 454 427 1 952 390 11 168 167 414      0 43 757 196
 August 6 574 636 3 002 514 10 083   7 328      0 41 609 231
 September 6 852 024 2 771 488 16 318   6 011      0 42 184 229
 October 6 837 718 2 604 261  6 752 142 553      0 44 129 217
 November 6 791 684 2 308 745  5 002  22 646      0 41 626 219
 December 6 799 549 2 039 322 28 829  69 738  2 999 37 682 237
2009
 January 6 915 963 2 706 912 37 614  31 659      0 38 295 253
 February 7 047 069 1 540 510 15 467  63 722  1 296 40 065 216
 March 7 156 361 3 116 003 10 101 782 157      0 44 021 251
 April 6 692 803 2 496 321  1 125 166 866      0 40 837 229
 May 7 278 237 3 365 177  1 802 113 453      0 44 890 240
 June 7 053 694 3 137 800 12 257  32 815      0 41 855 245
 July 7 884 633 3 196 888  3 994  65 574 41 781 43 457 258
 August 7 044 381 2 993 785 13 655 887 396  1 017 43 430 252
 September 7 149 828 2 926 934    427  28 303    124 42 375 238
 October 9 935 384 2 836 720  3 458 297 291    730 43 788 299
* Financial assets, software and intangible assets.
PDE = patient-day equivalent.
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DISCUSSION
A number of policy recommendations can be formulated from 
our study results. Our ﬁ ndings show that the total in-patient TB 
management costs at the hospital were on average US$2373 per 
TB patient, and that the main cost driver was the large number of 
in-patient days (97%). Laboratory tests, medication and PPE costs 
represented a much lower proportion. In general, the cost of TB 
control as a proportion of public health expenditure is relatively 
low.1 To reduce costs, the duration of in-patient stay should be 
shortened. It is, however, impossible to say where cost savings 
may be made on the basis of this study alone. An efﬁ ciency as-
sessment of the TB management programme has to be made be-
fore any recommendations can be proposed on cost reduction 
concerning in-patient days. 
The literature shows that community-based TB management is 
more cost-effective than clinic-based care.15 The cost of community-
based TB care in South Africa is estimated to be approximately 
US$392–US$766 per patient.15 It is difﬁ cult to compare these costs 
with the costs found in our study, as hospitalisation is often re-
quired for complex cases, such as MDR-TB patients and those with 
comorbidities (HIV/AIDS). This could be a reason for the high 
costs found in our study. It is not our intention to suggest that 
such patients should be treated in the community, unless they are 
well stabilised. Community-based treatment should not be seen as 
an alternative to in-patient care. More research is needed for in-
formation about the cost-effectiveness of both treatment options. 
We identiﬁ ed problems with adherence to the TB-IPC protocol 
in terms of the appropriate use of PPE, which is critical for the 
prevention of transmission and nosocomial TB infection.6 We 
may conclude that the overall use of PPE (especially masks) was 
poor among staff (26.3%), and even more so among visitors 
(15.8%). Patients with suspected MDR-TB were poorly monitored 
by staff. It should also be noted that PPE costs represented only a 
small proportion of the total costs (0.4%). This small investment 
could lead to major changes. If PPE is used optimally, new cases 
can be prevented, resulting in considerable cost reductions. For 
each TB case prevented using IPC measures, the hospital could 
save on average US$2373. Emphasis on PPE implementation is 
therefore important. Other options for improving adherence to 
the TB-IPC protocol should be investigated. 
This study has some limitations that should be addressed in 
future research. First, it did not address the efﬁ ciency and effec-
tiveness of anti-tuberculosis treatment at the hospital. Second, a 
substantial part of our study population did not have a record of 
costs at the NHLS or the pharmacy database. The laboratory and 
medication costs were slightly higher when these patients were 
excluded. Third, the cost of HIV/AIDS management was not in-
cluded. In South Africa, 53% of patients with TB are tested for 
HIV and of these, 60% are co-infected. The literature available on 
additional costs due to HIV co-infection is limited. The costs of 
HIV/AIDS management are known; however, due to the chronic 
nature of the disease, it is difﬁ cult to associate the additional costs 
incurred by TB patients. Further studies should include the extra 
costs for HIV/AIDS diagnosis and treatment. We assumed that TB-
HIV co-infection led to longer duration of hospital stay. In this 
study, HIV prevalence was difﬁ cult to measure due to the stigma 
attached to HIV/AIDS in South Africa and unclear notations in 
patients’ medical records.
Fourth, we assumed that patients who received different pre-
scriptions and large quantities of medication were suspected 
MDR-TB cases, as treatment costs for MDR-TB are substantially 
higher than for drug-susceptible TB.8 Recent data show that 1.8–
6.7% of pulmonary TB patients in South Africa have MDR-TB.1 
These patients account for higher laboratory costs due to drug 
susceptibility testing. Unfortunately, in our population the deﬁ ni-
tive diagnosis (TB or MDR-TB) was unknown. We do know that 
MDR-TB is associated with higher PPE costs. The literature shows 
that MDR-TB requires a prolonged treatment regimen, which 
means that these patients would have an increased length of stay.8 
As in-patient day costs account for most of our TB management 
costs, the costs for MDR-TB treatment should be much higher. 
In conclusion, this study shows that the costs associated with 
in-patient TB management at a CAH in South Africa are high. It is 
important to investigate whether anti-tuberculosis treatment 
FIGURE Total tuberculosis management costs at the central aca-
demic hospital. In-patient day costs per day and PPE costs per day 
were multiplied by average length of stay (9.7 days). PPE = personal 
protective equipment.
TABLE 5 PPE use
Patient
Ward/
single TB type
Staff Visitors
No. of 
entries
Surgical 
masks
n (%) 
Gloves*
n (%) 
Hand 
disinfectant
n (%) 
Apron
n (%)
No. of 
entries
Surgical 
masks
n (%)
Hand 
disinfectant
n (%)
1 Ward TB 13  3 (23)  8 (31) 3 (23) 1 (8) 13 1 (8) 0 
2 Ward TB 25  4 (16)  4 (8) 1 (4) 0  3 0 0 
3 Single MDR-TB 14 12 (86)  4 (14) 4 (29) 4 (29)  0 0 0 
4 Single MDR-TB 10  5 (50) 12 (60) 4 (40) 0  0 0 0 
5 Single TB 12  1 (8)  2 (8) 2 (17) 1 (8)  1 1 (100) 0 
6 Ward TB 22  3 (14) 10 (23) 4 (18) 0 11 1 (9) 0 
7 Single TB  7  2 (29)  2 (14) 1 (14) 4 (57)  4 1 (25) 2 (50)
8 Ward TB 25  2 (8) 12 (24) 4 (16) 1 (4)  8 0 1 (13)
9 Ward TB 38  1 (3)  8 (11) 3 (8) 0  9 0 0 
* Per pair.
PPE = personal protective equipment; TB = tuberculosis; MDR-TB = multidrug-resistant TB.
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needs to be moved to community-based care. PPE was not used 
properly. This indicates that training is required to ensure better 
adherence to TB-IPC protocol recommendations, given that the 
cost reduction per TB case prevented at the hospital was US$2373 
per saved case. 
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Contexte  :  On signale plus de cas de tuberculose (TB) en Afrique du 
Sud que dans n’importe quel autre pays, mais on ne dispose pas 
d’une estimation actualisée et précise des coûts liés au diagnostic, au 
traitement et à la prévention de la TB chez le patient hospitalisé. 
Objectif  :  Déterminer les coûts liés à la prise en charge des patients 
hospitalisés dans un hôpital académique central à Cape Town. En 
outre, on a étudié l’utilisation de l’équipement de protection du per-
sonnel (PPE).
Schéma  :  Etude de coût rétrospective et partiellement prospective à 
partir de patients diagnostiqués entre mai 2008 et octobre 2009.
Résultats  :  Le coût moyen d’une journée d’hospitalisation a été de 
US$238 par jour, la durée moyenne de séjour a été de 9,7 jours. Les 
coûts moyens pour le laboratoire ont été de US$6,82 par séjour, les 
coûts moyens de médicaments de US$8,68 par séjour et les coûts 
d’utilisation du PPE de US$0,99 par jour. Le coût moyen d’une prise 
en charge totale de la TB a été de US$2.373. Le PPE n’a pas toujours 
été utilisé correctement.
Discussion  :  Les coûts de la prise en charge d’un patient hospitalisé 
sont élevés par comparaison de ceux du traitement basé sur la collec-
tivité. La raison principale de ces coûts élevés est le nombre impor-
tant de journées d’hospitalisation. Une évaluation de l’efficience est 
nécessaire pour produire des recommandations permettant des ré-
ductions du coût. Les réductions de coût par cas de TB évité s’élèvent 
approximativement à US$2.373 par cas. L’utilisation du PPE est re-
sponsable des coûts les moins élevés. Une formation est nécessaire 
pour améliorer l’utilisation du PPE. 
Marco de referencia: En Sudáfrica se notifican más casos de tuber-
culosis (TB) que en ningún otro país, pero no se cuenta con un cál-
culo actualizado y preciso de los costos generados por el diagnóstico, 
el tratamiento y la prevención de la TB a escala intrahospitalaria. 
Objetivo: Determinar los costos asociados con el manejo de los paci-
entes hospitalizados por TB en un hospital universitario central en la 
Ciudad del Cabo. Se evaluó además la utilización de los dispositivos 
personales de protección (PPE). 
Método: Se llevó a cabo un estudio de costos, retrospectivo y par-
cialmente prospectivo, del tratamiento de los pacientes hospitaliza-
dos por TB entre mayo del 2008 y octubre del 2009. 
Resultados: El costo promedio por día de hospitalización fue US$238 
y la duración promedio de la estancia fue 9,7 días. El promedio de los 
costos de laboratorio por hospitalización fue US$26,82 y el promedio 
de los costos por medicamentos fue US$8,68. El costo del uso de los 
dispositivos personales de protección fue US$0,99 por día. El prome-
dio del costo total del tratamiento de la TB fue US$2373. El PPE no 
siempre se utilizó de manera adecuada. 
Conclusión: Los costos del tratamiento intrahospitalario de la TB son 
altos en comparación con los costos del manejo comunitario. La prin-
cipal razón del alto costo fue la prolongación de la estancia. Es pre-
ciso realizar una evaluación de la eficiencia, a fin de obtener reco-
mendaciones que contribuyan a disminuir los costos. La disminución 
de costos por cada caso de TB que se logra prevenir es de cerca de 
US$2373. El uso de los dispositivos personales de protección repre-
sentó la categoría con más bajo costo en el presupuesto. Es necesario 
impartir capacitación sobre la utilización de estos PPE.
